Announcements Trials
Browse Landscape

Phase

Phase 1 2Phase EARLY_PHASE1 1Phase 1/2 1

Status

Withdrawn 1Terminated 1Recruiting 1Active not recruiting 1

Sponsor Class

INDUSTRY 3OTHER 1

Study Type

Interventional 4

Sponsor

Cancer Type

Gynecologic 18Breast 11Gastrointestinal 4Thoracic 3Sarcoma 3Head & Neck 3Genitourinary 3

Conditions

Breast Neoplasms 9Colorectal Neoplasms 6Ovarian Neoplasms 4Triple Negative Breast Neoplasms 3Stomach Neoplasms 3Prostatic Neoplasms 3Endometrial Neoplasms 3Carcinoma, Non-Small-Cell Lung 3Uterine Cervical Neoplasms 2Small Cell Lung Carcinoma 2Pancreatic Neoplasms 2Neoplasm Metastasis 2Uterine Neoplasms 1Urologic Neoplasms 1Urinary Bladder Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Spinocerebellar Degenerations 1Sarcoma 1Lung Neoplasms 1Liposarcoma 1Esophageal Squamous Cell Carcinoma 1Digestive System Neoplasms 1Colonic Neoplasms 1Cholangiocarcinoma 1Carcinosarcoma 1Carcinoma, Ovarian Epithelial 1Carcinoma, Lobular 1Biliary Tract Neoplasms 1Adenocarcinoma of Lung 1Adenocarcinoma Of Esophagus 1

Interventions

pembrolizumab 50Cyclophosphamide 25Carboplatin 25Gemcitabine 20Cisplatin 19fludarabine 18Nivolumab 17Paclitaxel 16Bevacizumab 15Specimen Handling 14Fluorouracil 11Magnetic Resonance Spectroscopy 10aldesleukin 9Oxaliplatin 9Irinotecan 9Docetaxel 9Biopsy 9olaparib 8Trastuzumab 8durvalumab 7atezolizumab 7Hyperthermic Intraperitoneal Chemotherapy 7Albumin-Bound Paclitaxel 7Taxes 6Leucovorin 6Ipilimumab 6Interleukin-2 6Cetuximab 6Capecitabine 6130-nm albumin-bound paclitaxel 6

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Ovarian Neoplasms × Fulvestrant × Gastrointestinal × Clear all
NCT06257264 2026-06-05

A Study to Examine the Safety of Different Doses of BG-68501 Given to Participants With Advanced-Stage Tumors

BeOne Medicines

Phase 1 Active not recruiting
103 enrolled
BreastGastrointestinalGenitourinaryGynecologicThoracic

Urinary Bladder Neoplasms, Breast Neoplasms, Ovarian Neoplasms, Prostatic Neoplasms, Stomach Neoplasms, Endometrial Neoplasms, Small Cell Lung Carcinoma, Triple Negative Breast Neoplasms

NCT07109726 2026-05-22

A Phase 1/2 Trial of TER-2013 in Patients With Solid Tumors Harboring AKT/PI3K/PTEN Pathway Alterations

Terremoto Biosciences Inc.

Phase 1/2 Recruiting
205 enrolled
BreastGastrointestinalGynecologicHead & Neck

Squamous Cell Carcinoma of Head and Neck, Esophageal Squamous Cell Carcinoma, Breast Neoplasms, Uterine Cervical Neoplasms, Ovarian Neoplasms, Endometrial Neoplasms

NCT05252416 2025-11-28

(VELA) Study of BLU-222 in Advanced Solid Tumors

Blueprint Medicines Corporation

Phase 1 Terminated
50 enrolled
GastrointestinalGynecologicSarcoma

Adenocarcinoma Of Esophagus, Carcinosarcoma, Ovarian Neoplasms, Stomach Neoplasms, Endometrial Neoplasms

NCT05238831 2024-01-23

SMMART Adaptive Clinical Treatment (ACT) Trial

OHSU Knight Cancer Institute

Phase EARLY_PHASE1 Withdrawn
BreastGastrointestinalGenitourinaryGynecologicSarcoma

Breast Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Sarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡